Treatment for CSCR found to have “no benefit”

New research from the University of Bristol and University Hospital Southampton has concluded that eplerenone offers no benefit for patients suffering from central serous chorioretinopathy (CSCR), and subsequently should no longer be prescribed for the condition. Read more

BHVI strengthens East Asia presence in new deal

Epidemiological studies and clinical trials involving optical devices for myopia will be the focus of a new three-year agreement between the Brien Holden Vision Institute (BHVI) and a leading Chinese eye hospital network. Read more

© All Rights Reserved. All content published on this site is the property of Prime Creative Media. Unauthorised reproduction is prohibited

JOIN OUR NEWSLETTER

JOIN OUR NEWSLETTER
Close